Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Epeius reports anti-tumor activity of Rexin-G
The clinical trial design included five escalating doses of intravenous Rexin-G ranging from 1 x 10e11 cfu twice a week to 4 x 10e11 cfu three times a
The clinical trial design included five escalating doses of intravenous Rexin-G ranging from 1 x 10e11 cfu twice a week to 4 x 10e11 cfu three times a
These expanded label claims allow blood banks in Europe to use the Intercept Blood System in place of gamma irradiation for the prevention of transfusion-associated graft-vs.-host disease (TA-GVHD).
The drug candidate is a targeted nanoparticle, comprised of a proprietary, non-chemically-modified siRNA against the M2 subunit of ribonucleotide reductase – a clinically-validated cancer target – formulated with
The laboratory will place Orchid Cellmark close to its customers in the North West of England and is expected to provide expansion capacity to accommodate the award as
The approval follows a successful clinical trial involving more than 450 bridge-to-transplantation (BTT) patients, including those enrolled under continued access protocols, and a unanimous recommendation for approval from
The Stockert S5 is the fifth-generation of heart-lung machines and the successor to Sorin Group’s SIII perfusion system. The company claims that the S5 technology sets new standards
Surgical Care Affiliates’s (SCA’s) current president and CEO, Mike Snow, is resigning his position effective April 30, 2008, but will continue to serve as an advisor on the
The acquisition of the Xenon CT Perfusion technology is said to enhance NeuroLogica’s Portable CT capabilities in the emergency room, intensive care unit and operating room while increasing
These stores will now operate under The Medicine Shoppe name. The company acquired the Medicine Man pharmacies through an acquisition of assets as part of Park Pharmacy’s bankruptcy
Aart Brouwer, president of Celgene International, said: “We are working diligently with local regulatory authorities to determine next steps for pricing, reimbursement and distribution plans for all EU